Based on your current assessment of anti-TNF biosimilars, what is the optimal trajectory of these agents in the setting of RA and related immune-related conditions?

Based on your current assessment of anti-TNF biosimilars, what is the optimal trajectory of these agents in the setting of RA and related immune-related conditions?

Based on your current assessment of anti-TNF biosimilars, what is the optimal trajectory of these agents in the setting of RA and related immune-related conditions?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas